OBM Geriatrics

(ISSN 2638-1311)

OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.


Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period). 

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017

Special Issue

Age-Related Diseases

Submission Deadline: December 31, 2021 (Open) Submit Now

Guest Editor

Michael Fossel, MD, PhD

1. President of Telocyte (http://www.telocyte.com), Grand Rapids, MI 49503, USA
2. Retired Clinical Professor of Medicine, Michigan State University, Ada, MI 49301, USA

Website | E-Mail

Research Interests: human aging; telomeres; telomerase therapy; age-related diseases; Alzheimer's disease

About This Topic

The cause of aging is ignored by the same people who argue that aging is the greatest risk factor for their favorite disease.

Leonard Hayflick, 2019

Age-related diseases are the single greatest cause of mortality globally and are also the single greatest concern for those addressing issues of global healthcare expenditure, both now and in the projected future. The special issue on age-related disease will focus on age-related diseases of the CNS, vascular structures, joints, bones, renal system, and other systems and tissues. In every case, the diseases must be age-related and the papers should attempt to explain how the aging process plays a role in the pathology. Strong preference will be given to publishing innovative papers that (as suggested by Hayflick’s comment above) offer fundamental interventions in the aging process with either clinical potential or clinical trial data. Prospective papers may instead or also address broader geriatric issues, including symptomatic care, diagnostic methods, or the funding of age-related disease treatment at the local, national, or global levels. Specific age-related diseases might include relevant dementias (such as Alzheimer’s, Parkinson’s, FTD, etc.), cardiovascular diseases (such as myocardial infarction, coronary artery disease, aneurysm, stroke, peripheral vascular disease, congestive heart failure, etc.), osteoarthritis, osteoporosis, renal failure, skin aging, immunosenescence, or other age-related clinical syndromes, diseases, or presentations.